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Is there a genotype–phenotype 
correlation in primary 
hyperoxaluria type 1?
BB Beck1 and B Hoppe1
There is ongoing debate about a genotype-phenotype correlation 
in patients with primary hyperoxaluria type 1 and specific AGXT 
mutations. However, other determinants like environmental factors 
or modifer genes may play a pivotal role in the heterogeneity of 
the disease. The report of Lorenzo and co-workers highlights this 
situation, presenting data of a whole population with just one specific 
AGXT mutation.
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Th e term ‘primary hyperoxaluria type 1’ 
(PH1) refers to a hepatic defect in glyoxy-
late metabolism, namely a decrease or even 
loss of alanine:glyoxylate aminotransferase 
(AGT) activity. Th e disease itself causes no 
liver dysfunction but manifests as the most 
severe known urolithiasis entity. Th is is 
true with respect to both stone burden and 
prognosis. PH1 is considered to be rare 
but surely remains underreported with an 
estimated prevalence ranging from one to 
three per million population in Europe 
and North America.1 Higher rates are 
reported from inbred populations. Un- or 
misdiagnosed PH1 patients can defi ni-
tively be found in many dialysis programs, 
as a substantial proportion (up to >30%) 
of patients is diagnosed late with end-stage 
renal failure (ESRF) or, even worse, more 
or less by chance aft er a biopsy specimen 
is obtained for suspected renal graft  rejec-
tion. There are several reasons for this 
dilemma. One is unfamiliarity with the 
rare monogenic disorder presenting with 
urolithiasis and with the linkage between 
stones and metabolic disorders. Th e fact 
that about half the children with stones, 
surprisingly, do not complain about pain 
or do so very little may unfortunately sup-
port this attitude. Second, while ESRF due 
to PH1 fortunately is rare in childhood, a 
number of patients are seen only in adult 
nephrology departments, which might 
make it more acceptable or simply neces-
sary to treat patients without established 
diagnosis. Th ird, with anuria present, the 
most valuable screening instrument, the 
determination of urinary oxalate excre-
tion, is no longer available.
PH1 is a mendelian disorder of auto-
somal-recessive inheritance with abso-
lute penetrance but extremely variable 
expressivity. Th e enzyme physiologically 
allocated to liver peroxisomes converts 
glyoxylate to glycine. In its absence or 
because of mistargeting to mitochondria, 
glyoxylate will be increasingly converted 
to oxalate and glycolate (Figure 1). Oxalate 
cannot be further metabolized in humans 
and therefore has to be cleared by the kid-
ney. Unfortunately, urine becomes quickly 
supersaturated with marked endogenous 
oxalate production. Nephrocalcinosis, 
which is crystal deposition within the dis-
tal tubular and collecting duct lumen, and 
recurrent stone formation are the clinical 
hallmarks of PH1 (Figure 1).1
Progressive nephrocalcinosis and recur-
rent urolithiasis along with their second-
ary complications (chronic interstitial 
infl ammation and fi brosis) result some-
how in chronic renal failure, which usu-
ally progresses to ESRF over time. Much 
worse than that, once signifi cant loss of 
renal function occurs, systemic deposi-
tion of calcium oxalate (systemic oxalosis) 
invariably takes place in various tissues, 
including the retina, myocardium, ves-
sel walls, central nervous system, bones, 
skin, and many more. Th is superimposes 
additional morbidity — for example, 
blindness; cardiomyopathy; arrhythmias, 
including heart block; oxalate osteopathy; 
treatment-resistant anemia; and so on.1 
No form of dialysis treatment will stop or 
reverse systemic oxalate deposition. Many 
of the complications take years to reverse 
aft er combined kidney–liver transplanta-
tion; sadly, some, such as loss of vision, 
are irreversible.
The remarkable single-center study 
by Lorenzo and co-workers2 (this issue) 
describes impressively the devastating 
course of systemic oxalosis not in a single 
patient but for a whole population — no 
small thing considering the relative paucity 
of long-term data. Th ey clearly outline sev-
eral key points regarding the clinical course 
of PH1:
(1)  PH1 patients who stay on chronic 
(hemo)dialysis are likely to die from 
systemic oxalosis.
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(2)  Time spent on (hemo)dialysis should 
be kept to the absolute minimum.
(3)  Patients deserve a high priority on the 
waiting list for combined liver–kidney 
transplantation.
(4)  Early diagnosis by liver biopsy and/or 
mutational analysis as well as timely 
medical therapy is of paramount 
importance.
Since PH1 became apparent as an 
entity, physicians have wondered about 
the remarkable clinical heterogeneity of 
the disease. Symptoms can develop in a 
small subset of patients (10%) as early as 
the neonatal period, and all such patients 
develop rapid ESRF within a few weeks 
to months. Th e vast majority of patients 
will present in childhood and reach ESRF 
between the second and fourth decades of 
life. Individuals who manifest late in life, 
an even smaller group (<10%), represent 
the reverse side of the PH1 spectrum. 
Some of them have true late-onset cases of 
PH1, whereas others have revealed signs 
and symptoms before but remained undi-
agnosed. Th is latter group oft en presents 
with advanced renal failure.
Starting with the ground-breaking 
studies performed by Danpure and col-
leagues, our understanding of the genetic 
and molecular mechanisms involved in 
PH1 has greatly evolved over the past 
20 years.1 Today more than 60 mutations 
in the alanine:glyoxylate aminotransferase 
(AGXT) gene located on chromosome 
2q37.3, resulting in subsequent absolute 
or functional enzyme deficiency, have 
been published. Th ere is no mutational 
hot spot, but various mutations have 
been found throughout the 11 exons of 
the AGXT gene, which makes mutational 
analysis a sometimes laborious investiga-
tion. Many more are likely to be reported 
in the future. Th e G508A missense muta-
tion (20%–30% allelic frequency) is most 
commonly found in PH1 and results in 
AGT mistargeting from the peroxisomes 
to the mitochondria. Another frequently 
(6%–9%) encountered missense mutation, 
I244T, leads to AGT misfolding, which 
produces functionally inactive aggre-
gates.3 Not surprisingly, PH1 proved to 
be equally heterogeneous on the molecu-
lar level. So it seemed quite tempting to 
explain clinical heterogeneity by genetics. 
Keeping in mind the grim consequences 
of renal failure and the risks involved with 
liver transplantation, predicting the natu-
ral outcome for each patient would be a 
powerful tool, allowing sound counseling 
and a tailored medical management. For 
all the noble eff orts by diff erent investi-
gators, so far all attempts to establish a 
general genotype–phenotype correlation 
have failed.4–6
Th ere are several reasons why a geno-
type–phenotype correlation is so diffi  cult 
or, as some experts believe, even impos-
sible to prove. Besides the magnitude of 
mutations found, most individuals from 
non-consanguineous families are com-
pound heterozygous, which makes a large 
group necessary to avoid skewing of the 
data. Unfortunately, such numbers are not 
available at the moment. In the available 
studies one can easily spot controversial 
fi ndings where a certain genotype is asso-
ciated with a favorable outcome in one but 
an unfavorable outcome in another study. 
Patients from consanguineous families 
often show private mutations not dis-
covered in other individuals. Moreover, 
in some families, extreme intrafamil-
ial phenotype variation exists, ranging 
from infantile oxalosis to a seemingly 
asymptomatic relative despite identical 
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Figure 1 | Oxalate metabolism in patients with primary hyperoxaluria types 1 and 2 and clinical 
hallmarks: severe urolithiasis and either medullary or diffuse nephrocalcinosis. AGT, alanine:
glyoxylate aminotransferase; GO: glycolate reductase; HPR: hydroxypyruvate reductase. (Scheme 
modified from Leumann and Hoppe, with permission.1)
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genotype.7,8 It should be mentioned, 
however, that two remarkable retrospec-
tive studies independently described an 
association between the G508A mutation 
and pyridoxine response, with a greater 
reduction of urinary oxalate excretion 
to near normal levels in homozygous 
patients, but a still partial response in 
heterozygous individuals.4,6 Pyridoxine 
treatment, the essential cofactor used by 
all aminotransferase reactions, has been 
reported for PH1 since the 1960s, long 
before AGT defi ciency was discovered. 
Despite systematically evaluating pyri-
doxine response in all our patients, we, 
however, are unable to confi rm these asso-
ciations and still await the fi rst patient to 
show complete response.
Th at is what makes the contribution of 
Lorenzo et al.2 so important, as it should 
off er some guidance in all this discussion. 
If there is a genotype–phenotype correla-
tion, it is likely to be found in the popula-
tion described. Unlike most patients who 
are compound heterozygous bearing two 
diff erent mutations, interestingly, more 
than 90% of PH1 among Canary Islands 
inhabitants is caused by the I244T mis-
sense mutation, with almost all patients 
being homozygous.3 To date, I244T con-
stitutes the only PH1 mutation associated 
with a founder eff ect. Looking at the data 
of Lorenzo et al.2 we feel unhappy again; 
no uniform phenotype appears even in 
this small population characterized by 
genetic isolation.
So is PH1 no longer considered a 
monogenic disease? For all we know, 
this is still the case; at least no other gene 
responsible has been identifi ed. How-
ever, it is increasingly recognized that 
mendelian disorders are infl uenced by 
modifi er genes that transform the phe-
notype into more complex traits. In order 
to uncover environmental factors and 
modifi er genes, promising results came 
from animal studies of gastrointestinal 
oxalate transport, where secretory path-
ways for extrarenal oxalate elimination 
have been recently identifi ed.9 Oxalo-
bacter formigenes is an obligate anaero-
bic bacterium naturally colonizing the 
intestinal tract, which uses oxalic acid 
as its sole source of energy. Absence of 
O. formigenes colonization is observed 
in recurrent calcium oxalate stone form-
ers. Hatch et al. were able to demonstrate 
that intestinal degradation of oxalate by 
O. formigenes in hyperoxaluric rats with 
renal insuffi  ciency can induce excretion 
of oxalate from the blood to the intes-
tinal lumen.9 Following that, we were 
able to show that treatment with O. for-
migenes in PH1 leads to a considerable 
reduction of urinary oxalate excretion or 
plasma oxalate levels in ESRF patients.10 
Until recently the molecules in epithe-
lial oxalate transport were unknown, 
but a new study by Jiang et al. shows that 
mice with knockout of Slc26a6 (an anion 
exchanger expressed in kidney and intes-
tinal epithelial tissue) develop a pheno-
type that resembles PH1.11
Concluding our remarks, we strongly 
feel that a specifi c genotype–phenotype 
correlation is more than diffi  cult to obtain 
in patients with PH1. Heterogeneous as 
this disease is, environmental factors and 
modifi er genes may play a more important 
role than currently anticipated. In addi-
tion, with a better awareness of the disease 
and hence higher prevalence numbers, a 
more profound basis would be available to 
answer whether a true genotype–pheno-
type correlation exists.
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